Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft standard CEI-MS-07: Sub-visible particulate matter in… — submissions

The 13 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-088/2
Series
Public comment period
Version
1.0
Published
21 Jul 2026
Last reviewed
21 Jul 2026
Next review
21 Jul 2027
Identifier
10.71829/cei.cp.88
Certainty
Not rated
Cycle
2026 Q3
Window
21 Jul 2026 – 19 Sep 2026
Status
Open
Submissions
13

§2Submissions and responses

13 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Jerome Petrossian, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-PARTICULATE-/002 received 24 Jul 2026

The standard does not state that a determination on one unit says nothing about the batch

The respondent states that determinations under this standard are generally performed on a single unit and that certificates then travel with every unit of a batch, so that a single-unit result is routinely read as a batch result.

The respondent proposes that the standard require a sampling statement on the face of every determination.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseAccepted04 Oct 2026

The secretariat accepts this submission. The inference from unit to batch is the most consequential unstated assumption in supply documentation.

Every determination made under this standard now carries a sampling statement recording how many units were sampled, from what population and by what plan, and the standard states that a determination on a single unit supports no inference about any other unit.

Dr Quentin Whitmarsh-Obi, MD, FRCS Academic peptide-chemistry group
DRAFT-PARTICULATE-/007 received 29 Jul 2026

A determination does not record the version of the standard it was made under

The respondent states that the standard will be revised and that results reported under different versions will circulate together, indistinguishable from one another.

The respondent proposes that the standard identifier and version be carried on the face of every determination.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted05 Oct 2026

The secretariat accepts this submission. A conformance claim against an unspecified version is not a conformance claim.

Every determination reported under this standard now carries the standard identifier and version on its face, and a claim of conformance that does not identify the version is recorded by the Institute as not conformant.

Dr Delphine Trelawney, MSc (Regulatory Affairs) Public-sector clinical trials unit
DRAFT-PARTICULATE-/008 received 07 Aug 2026

The search date is not on the face of the document

The draft carries a publication date and a review date but not the date on which the evidence was last searched. Those are three different dates and only the third tells a reader how current the assessment is. A document published in one quarter may rest on a search run two quarters earlier, and nothing on the page allows that gap to be measured.

The respondent proposes that the search date be printed adjacent to every certainty rating rather than in the methods section, on the ground that a reader who acts on a rating is unlikely to have read the methods section first.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted06 Oct 2026

The secretariat accepts this submission. The distinction between publication, review and search dates is real and the draft did not make it visible where it mattered.

The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.

Dr Kamila Ubertini, PharmD, BCPS Regulatory affairs, generic medicines sector
DRAFT-PARTICULATE-/009 received 10 Aug 2026

The standard does not say what to do with a result outside the expected range

The respondent states that the draft describes how to obtain a result and stops, and that the handling of an unexpected result is where the integrity of a determination is decided.

The respondent proposes that repetition be permitted only under stated conditions and that every determination performed be reported, including those superseded.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted27 Sep 2026

The secretariat accepts this submission. A standard silent on repetition permits the selective reporting it exists to prevent.

The standard now requires that every determination performed on a sample be reported, that a repeat be permitted only where an assignable cause is documented, and that the assignable cause be stated on the face of the report.

Dr Zebedee Zaleski-Mbeki, PhD (Pharmaceutics) Endocrine surgery service
DRAFT-PARTICULATE-/011 received 17 Aug 2026

A system suitability criterion is unachievable on instrumentation in general use

The respondent, employed by a contract analytical laboratory, states that one of the suitability criteria in the draft can be met only on current-generation instrumentation, and that laboratories operating validated older systems would be unable to report a conformant determination.

Data from three instruments of different generations, showing the criterion met on one and missed on two, accompanied the submission.

Declared interest. Employed by a health technology assessment body that has issued guidance on a compound named in the draft.
Secretariat responseAccepted in part05 Oct 2026

The secretariat accepts this submission in part. The criterion is relaxed to the level the supplied data support for the general case, and retained at the stricter level for the specific discrimination that motivated it.

The suitability criterion is now stated at two levels, a general level achievable on instrumentation in common use and a stricter level required only where the standard is applied to the discrimination named in the scope, with the reason for the difference stated.

Dr Ottoline Oppenheimer-Ade, MD, MPH Primary-care research network
DRAFT-PARTICULATE-/005 received 20 Aug 2026

A single determination is permitted where duplicates would be inexpensive

The respondent states that the draft permits a result to be reported from one injection, and that the marginal cost of a duplicate is small relative to the value of detecting a preparation error.

The respondent proposes that duplicate determinations be mandatory.

Declared interest. Has received honoraria for educational lectures from a marketing-authorisation holder of a compound named in the draft, within the preceding three years.
Secretariat responseAccepted in part03 Oct 2026

The secretariat accepts this submission in part. Duplicate preparation and injection are required, and a criterion for agreement between them is stated. The proposal to require full duplicate sample preparation on separate days is declined as disproportionate.

The standard now requires duplicate preparation and injection with a stated maximum difference between the two, and requires that a difference exceeding it be investigated before any figure is reported.

Dr Quintus Kettlewell, PharmD, MSc National medicines information service
DRAFT-PARTICULATE-/004 received 21 Aug 2026

The reporting threshold is not tied to a demonstrated limit of quantitation

The draft sets a reporting threshold as a fixed percentage. The respondent states that whether a laboratory can quantify at that threshold depends on the signal-to-noise achieved, and that the threshold should be conditional on demonstrating it.

The respondent proposes that a determination be reportable only where the signal-to-noise at the threshold is demonstrated in the run.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted15 Oct 2026

The secretariat accepts this submission. A threshold no one has demonstrated is a convention rather than a limit.

The reporting threshold is now conditional on demonstrating the required signal-to-noise at that threshold within the run, and a determination that cannot demonstrate it reports the achievable threshold instead of the nominal one.

Dr Hortensia Larsson-Ekwueme, MSc (Regulatory Affairs) Public-sector clinical trials unit
DRAFT-PARTICULATE-/006 received 26 Aug 2026

Terms are used in senses that differ from established pharmacopoeial usage

The respondent, employed by a national competent authority and writing in a personal capacity, identifies three terms used in the draft in senses that differ from their established pharmacopoeial meanings.

The respondent proposes that established usage be followed or that the departure be stated explicitly at first use.

Declared interest. Employed by a university department that has received unrestricted research funding from a manufacturer of a compound in the class under assessment. The respondent had no role in that funding.
Secretariat responseAccepted05 Oct 2026

The secretariat accepts this submission. A term used in a private sense inside a document that will be read alongside compendial texts is a source of avoidable error.

The three terms now follow established pharmacopoeial usage, the glossary records the definition and its source, and where the Institute uses a term in a narrower sense the departure is stated at first use in the standard.

Dr Oswin Yorkstone, PhD (Pharmacology) Hospital microbiology and endotoxin testing service
DRAFT-PARTICULATE-/010 received 30 Aug 2026

The standard assumes a reference standard of known assigned content

The respondent states that for many compounds in scope no reference standard with an assigned content exists, and that the standard as drafted has nothing to say to a laboratory in that position.

The respondent proposes that the standard state what can be determined without one and how such a determination should be labelled.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted28 Sep 2026

The secretariat accepts this submission. A standard applicable only where a reference standard exists is silent in the cases most in need of it.

The standard now states which determinations remain available without a reference standard of assigned content, requires that such determinations be labelled as relative rather than absolute, and requires the assumption used in place of an assigned content to be stated.

Dr Theodora Ximenes, PhD (Pharmaceutics) Endocrine surgery service
DRAFT-PARTICULATE-/001 received 31 Aug 2026

The standard should state a pass limit

The respondent states that a standard which reports a figure without a limit leaves the reader without a criterion, and that suppliers will set their own.

The respondent proposes a universal acceptance limit for the determination.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseNot accepted04 Oct 2026

The secretariat does not accept this submission. An appropriate limit depends on the compound, the presentation and the intended route, none of which the standard fixes.

The standard states performance and reports the figure as determined. Setting a universal limit would attach a pass or fail to materials whose acceptable ranges genuinely differ, which would be a stronger claim than the Institute can support. The submission remains published in full and the point is recorded in the limitations.

Dr Wolfram Kaltenbach-Mensah, PhD (Toxicology) Health-technology assessment agency
DRAFT-PARTICULATE-/013 received 05 Sep 2026

The document set should be published in translation

The respondent notes that the assessments concern compounds supplied internationally and that publishing only in English restricts access to the assessment to readers who work in it.

The respondent proposes machine translation of the document set as an interim measure, with human review of the certainty language.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseNot accepted10 Oct 2026

The secretariat does not accept this submission, and records that the underlying point is sound and that the proposed remedy is the difficulty.

A translation whose certainty language has drifted is a different assessment carrying the Institute's name, and the Institute cannot review translations it does not have the capacity to review. The documents remain in English. The submission is published in full because the access problem it identifies is real and unresolved.

Dr Ottoline Fitzgerald-Nwosu, MD, MRCP Independent analytical consultancy
DRAFT-PARTICULATE-/012 received 15 Sep 2026

A field classified as critical is not one a reading turns on

The respondent examines the fields classified as critical and states that two of them are administrative rather than interpretive, so that a certificate could be rendered uninterpretable by an omission that changes no reading.

The respondent proposes that a field be classified critical only where its absence changes what the figure means.

Declared interest. No interest to declare. The respondent is a graduate student and states that the submission forms no part of any assessed work.
Secretariat responseAccepted in part30 Sep 2026

The secretariat accepts this submission in part. One field is reclassified as recommended on the test the respondent proposes. The second is retained as critical because its absence prevents the determination being attributed to a batch.

The classification test is now stated in the standard: a field is critical where its absence changes the meaning of a reported figure or prevents attribution to a batch. One field has been reclassified under that test and the reasoning recorded.

Dr Theodora Ingelbrecht, MSc, CChem Academic sports-medicine and anti-doping laboratory
DRAFT-PARTICULATE-/003 received 18 Sep 2026

A conformance claim is not defined and will be made loosely

The respondent states that the draft nowhere defines what it means for a determination to conform, and that in the absence of a definition the phrase will be applied to determinations that meet some of the requirements.

The respondent proposes an explicit definition and a requirement that partial conformance be described as such.

Declared interest. Employed by an analytical laboratory that performs contract testing for suppliers, including at least one supplier named in the Institute's assessment set.
Secretariat responseAccepted28 Sep 2026

The secretariat accepts this submission. An undefined conformance claim is a marketing phrase.

Conformance is now defined as meeting every requirement classified as critical together with the stated system suitability criteria, partial conformance must be described by naming the requirements not met, and a claim of conformance made without the sampling statement is not conformant.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.